lobbying_filings_raw: 630dd0dc-ef9b-4272-8563-21312b5416f4
This data as json
| filing_uuid | filing_type | registrant_id | registrant_name | client_id | client_name | filing_year | filing_period | received_date | is_amendment | is_no_activity | is_termination | raw_json | registrant_state | registrant_country | registrant_house_id | client_state | client_ppb_state | client_country | client_ppb_country | client_general_description | client_government_entity | affiliated_org_count | client_entity_id | client_government_unit_id | client_match_method | client_match_confidence | income_amount | expense_amount |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 630dd0dc-ef9b-4272-8563-21312b5416f4 | Q1 | 401103351 | CAPITALHILL ADVISORY | 198646 | NOVARTIS PHARMACEUTICALS PTY LTD ( AUSTRALIA) | 2015 | first_quarter | 2015-04-08T23:23:14.047000-04:00 | 0 | 0 | 0 | {"url": "https://lda.senate.gov/api/v1/filings/630dd0dc-ef9b-4272-8563-21312b5416f4/", "filing_uuid": "630dd0dc-ef9b-4272-8563-21312b5416f4", "filing_type": "Q1", "filing_type_display": "1st Quarter - Report", "filing_year": 2015, "filing_period": "first_quarter", "filing_period_display": "1st Quarter (Jan 1 - Mar 31)", "filing_document_url": "https://lda.senate.gov/filings/public/filing/630dd0dc-ef9b-4272-8563-21312b5416f4/print/", "filing_document_content_type": "text/html", "income": null, "expenses": null, "expenses_method": null, "expenses_method_display": null, "posted_by_name": "Cathy Duncan", "dt_posted": "2015-04-08T23:23:14.047000-04:00", "termination_date": null, "registrant_country": "United States of America", "registrant_ppb_country": "Australia", "registrant_address_1": "1717 Pennsylvania Ave NW Suite 1025", "registrant_address_2": null, "registrant_different_address": false, "registrant_city": "Washington", "registrant_state": "DC", "registrant_zip": "20006", "registrant": {"id": 401103351, "url": "https://lda.senate.gov/api/v1/registrants/401103351/", "house_registrant_id": null, "name": "CAPITALHILL ADVISORY", "description": "Corporate and Government Relations Consulting", "address_1": "1717 Pennsylvania Ave NW Suite 1025", "address_2": null, "address_3": null, "address_4": null, "city": "Washington", "state": "DC", "state_display": "District of Columbia", "zip": "20006", "country": "US", "country_display": "United States of America", "ppb_country": "AU", "ppb_country_display": "Australia", "contact_name": "CATHY DUNCAN", "contact_telephone": "", "dt_updated": "2022-04-06T16:07:35.480058-04:00"}, "client": {"id": 198646, "url": "https://lda.senate.gov/api/v1/clients/198646/", "client_id": 24, "name": "NOVARTIS PHARMACEUTICALS PTY LTD ( AUSTRALIA)", "general_description": "Pharmaceutical Company", "client_government_entity": false, "client_self_select": null, "state": null, "state_display": null, "country": "AU", "country_display": "Australia", "ppb_state": null, "ppb_state_display": null, "ppb_country": "AU", "ppb_country_display": "Australia", "effective_date": "2014-07-15"}, "lobbying_activities": [{"general_issue_code": "PHA", "general_issue_code_display": "Pharmacy", "description": "Australian government policy on intellectual property and its impact on the Australian healthcare system", "foreign_entity_issues": "Impact of Australian Government policy on the company's local business environment", "lobbyists": [{"lobbyist": {"id": 60865, "prefix": null, "prefix_display": null, "first_name": "NICHOLAS", "nickname": null, "middle_name": null, "last_name": "CAMPBELL", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 39, "name": "State, Dept of (DOS)"}]}, {"general_issue_code": "TRD", "general_issue_code_display": "Trade (domestic/foreign)", "description": "Australian government policy on intellectual property and its impact on the Australian healthcare system", "foreign_entity_issues": "Impact of Australian Government policy on the company's local business environment", "lobbyists": [{"lobbyist": {"id": 60865, "prefix": null, "prefix_display": null, "first_name": "NICHOLAS", "nickname": null, "middle_name": null, "last_name": "CAMPBELL", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 39, "name": "State, Dept of (DOS)"}]}, {"general_issue_code": "CPT", "general_issue_code_display": "Copyright/Patent/Trademark", "description": "Australian government policy on intellectual property and its impact on the Australian healthcare system", "foreign_entity_issues": "Impact of Australian Government policy on the company's local business environment", "lobbyists": [{"lobbyist": {"id": 60865, "prefix": null, "prefix_display": null, "first_name": "NICHOLAS", "nickname": null, "middle_name": null, "last_name": "CAMPBELL", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 39, "name": "State, Dept of (DOS)"}]}, {"general_issue_code": "HCR", "general_issue_code_display": "Health Issues", "description": "Australian government policy on intellectual property and its impact on the Australian healthcare system", "foreign_entity_issues": "Impact of Australian Government policy on the company's local business environment", "lobbyists": [{"lobbyist": {"id": 60865, "prefix": null, "prefix_display": null, "first_name": "NICHOLAS", "nickname": null, "middle_name": null, "last_name": "CAMPBELL", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 39, "name": "State, Dept of (DOS)"}]}], "conviction_disclosures": [], "foreign_entities": [], "affiliated_organizations": []} | DC | US | AU | AU | Pharmaceutical Company | 0 | 0 |